Clinical characteristics and outcome of autoimmune pancreatitis based on serum immunoglobulin G4 level: A single-center, retrospective cohort study

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains a significant public health challenge and is currently the fourth leading cause of cancer-related mortality in developed countries. Despite advances in cancer treatment, the 5-year survival rate for patients with PDAC remains less than 5%. In recent years, neoadjuvant therapy (NAT) has emerged as a promising treatment option for many cancer types, including locally advanced PDAC, with the potential to improve patient outcomes. To analyze the role of NAT in the setting of locally advanced PDAC over the past decade, a systematic literature search was conducted using PubMed and Web of Science. The results suggest that NAT may reduce the local mass size, promote tumor downstaging, and increase the likelihood of resection. These findings are supported by the latest evidence-based medical literature and the clinical experience of our center. Despite the potential benefits of NAT, there are still challenges that need to be addressed. One such challenge is the lack of consensus on the optimal timing and duration of NAT. Improved criteria for patient selection are needed to further identify PDAC patients likely to respond to NAT. In conclusion, NAT has emerged as a promising treatment option for locally advanced PDAC. However, further research is needed to optimize its use and to better understand the role of NAT in the management of this challenging disease. With continued advances in cancer treatment, there is hope of improving the outcomes of patients with PDAC in the future.

Can serum immunoglobulin G4 levels and age serve as reliable predictors of relapse in autoimmune pancreatitis?

“…In conclusion, the clinical research paper authored by Zhou et al [ 1 ] provides plausible, albeit not entirely compelling, evidence suggesting a predictive role of elevated serum IgG4 levels and advanced age in the relapse of AIP. These findings, while intriguing, warrant further validation through prospective, multi-center studies with larger sample sizes.…”

“…We are writing in response to the recent clinical research paper published in the World Journal of Gastroenterology by Zhou et al [ 1 ]. In their study, the authors presented a cohort of 213 patients diagnosed with autoimmune pancreatitis (AIP), assigned to two groups based on serum immunoglobulin (Ig) G4 levels.…”

“…Specifically, 148 patients were assigned to the abnormal group with serum IgG4 levels exceeding 2-fold the upper limit of the reference range, while 65 patients belonged to the normal group with serum IgG4 levels at or below this threshold. Through a comprehensive comparison of clinical characteristics and outcomes between these two groups, Zhou et al [ 1 ] identified higher serum IgG4 levels and age over 55 years as independent risk factors for disease relapse.…”

“…The implications of these results are noteworthy, as they may guide clinicians in developing more targeted and effective management strategies for AIP patients. The study conducted by Zhou et al [ 1 ] provides a solid foundation for further discussions and investigations in the field of AIP, shedding light on potential paths for improved patient care and outcomes.…”